- Case Report
- Open Access
Recurrent intraventricular thrombus six months after ST-elevation myocardial infarction in a diabetic man: a case report
© Lacalzada et al.; licensee BioMed Central Ltd. 2013
- Received: 20 May 2013
- Accepted: 29 August 2013
- Published: 2 September 2013
Percutaneous coronary intervention with placement of a drug-eluting stent in a diabetic patient with ST-elevation myocardial infarction is a relatively common procedure, and always requires subsequent treatment with dual antiplatelet therapy. It is sometimes necessary to add oral anticoagulation therapy because of individual clinical circumstances, which further increases the risk of bleeding.
A 66-year-old hypertensive diabetic man with a history of gastrointestinal bleeding was admitted with an ST-elevation inferior myocardial infarction that had been evolving over 72 h. Electrocardiography showed ST segment elevation in the inferior leads and Q waves in the inferior and anterior leads. He reported a similar episode of chest pain 1 month previously, for which he had not sought medical treatment. Coronary angiography showed chronic occlusion of the mid-left anterior descending coronary artery, and acute occlusion of the mid-right coronary artery. He was treated by percutaneous coronary intervention, with placement of a drug-eluting stent in the right coronary artery. Soon after admission, transthoracic echocardiography showed abnormal left ventricular contractility and a large left intraventricular thrombus. Three weeks after admission, the patient was discharged on dual antiplatelet therapy (clopidogrel and aspirin) and oral anticoagulation therapy (acenocoumarol). Four months after discharge, transthoracic echocardiography showed absence of left ventricular thrombus and resolution of the abnormal contractility in the area supplied by the revascularized right coronary artery. Given the high risk of bleeding, oral anticoagulation therapy was stopped. Six months later, transthoracic echocardiography showed recurrent left ventricular apical thrombus, and an underlying hypercoagulable state was ruled out. Oral anticoagulation therapy was restarted on an indefinite basis, and dual antiplatelet therapy was continued.
The present case illustrates the need for repeat transthoracic echocardiography following the withdrawal of oral anticoagulation therapy in patients with ST-elevation myocardial infarction, both to monitor thrombus status and to assess left ventricular segmental contraction. In patients who require anticoagulation, avoidance of a drug-eluting stent is strongly preferred and second-generation stents are recommended. The alternative regimen of oral anticoagulation and clopidogrel may be considered in this scenario. In patients with recurrent intraventricular thrombus an underlying hypercoagulable state should be ruled out.
- Acute myocardial infarction
- Percutaneous coronary intervention
- Drug-eluting stent
- Intraventricular thrombus
- Dual antiplatelet therapy
- Oral anticoagulation
Use of drug-eluting stents in diabetic patients with ST-elevation myocardial infarction (STEMI) is relatively common, and subsequent treatment with dual antiplatelet therapy (DAPT) is invariably required . Concomitant oral anticoagulation therapy (OAC) is sometimes necessary if the patient has left ventricular (LV) apical thrombus. Current guidelines on the management of patients with STEMI emphasize the role of transthoracic echocardiography (TTE) for assessment of the extent and degree of wall motion abnormalities and mural thrombi that would necessitate anticoagulation . However, the lack of prospective randomized studies precludes the development of firm recommendations regarding the use of triple antithrombotic therapy (combined OAC and DAPT) in patients at high risk of bleeding. The European Heart Journal guidelines of 2012  state that patients with mural thrombi require OAC with vitamin K antagonist therapy for up to 6 months. According to the 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines , vitamin K antagonist therapy can be limited to 3 months in patients who have LV thrombus or are at risk for LV thrombus, such as patients with antero-apical akinesis or dyskinesis.
Triple antithrombotic therapy increases the risk of bleeding, and the optimal duration of triple therapy is unclear, especially in the era of stenting and DAPT. Decisions regarding administration of triple therapy after STEMI should consider stent placement, stent type, and the relative risks of bleeding and stent thrombosis [4, 5].
If LV imaging after 3 months of therapy shows no evidence of thrombus, discontinuation of OAC earlier than 6 months can be considered, especially if there is recovery of apical wall motion . Given the increased risk of bleeding related to dual and triple antithrombotic therapy, it would be desirable to test simpler drug combinations, and to clarify the optimal duration of treatment for prevention of further ischemic/thrombotic events.
We present here an elderly diabetic and hypertensive man who was admitted with acute inferior STEMI. He reported an episode of severe chest pain 1 month previously, for which he had not sought medical treatment. We discuss the unexpected developments and the resolution of his intraventricular thrombus, as well as potential emerging management strategies for such patients.
Our decision to perform PCI with placement of a DES at the acute RCA lesion was guided by our patient’s diabetes and the evolving inferior myocardial infarction, after myocardial viability was confirmed on cardiovascular magnetic resonance imaging, in accordance with the current recommendations [1, 7]. The reported chest pain 1 month before his admission and his ECG changes suggested an old anterior myocardial infarction. This was confirmed by changes in LV segmental contraction observed on TTE and invasive coronary angiography. The patient was discharged on DAPT, to be continued for at least 6 months, because of the type of stent used. OAC was also prescribed because of the LV apical thrombus, which was adjacent to the percutaneously revascularized ischemic endocardium. This therapeutic combination clearly increased the risk of bleeding, especially considering the patient’s age and history of hypertension and gastrointestinal bleeding . The current consensus is that patients with mural thrombi should take OAC with vitamin K antagonist therapy for up to 6 months. However, this recommendation has not been revised in the era of stenting and DAPT. The optimal duration of triple antithrombotic therapy is unknown, and decisions regarding therapy should consider the relative risks of bleeding and stent thrombosis. If LV imaging after 3 months of therapy shows no evidence of thrombus, discontinuation of OAC earlier than 6 months can be considered, especially if there is recovery of apical wall motion . Some authors have concluded that the duration of vitamin K antagonist therapy can be limited to 3 months in patients who have LV thrombus or are at risk for LV thrombus, such as those with antero-apical akinesis or dyskinesis, and that the duration of DAPT required may depend on the type of stent . In our patient, follow-up TTE showed resolution of both the thrombus and the abnormal contractility of the apical-inferior and inferior LV supplied by the revascularized RCA. Our decision to stop OAC after 4 months was based on these findings, but DAPT was continued. However, the subsequent recurrence of thrombus in the same location suggests that thrombus formation was related to the non-revascularized apical-anterior and apical-septal myocardial segments, which were supplied by the left anterior descending coronary artery and had infarcted prior to admission.
There are some previous reports of cases similar to ours, in which LV thrombus recurred after discontinuation of OAC, causing cardioembolism years after STEMI [9, 10]. When triple antithrombotic therapy is used, an international normalized ratio (INR) target range of 2.0 to 2.5 is reasonable , although prospective data for such treatment are lacking. Our patient had INR values between 2 and 3 in all follow-up tests, so we assume that the recurrent apical thrombus was not attributable to a failure of medical treatment. As he had risk factors for atherothrombosis, we did not initially suspect an underlying hypercoagulable state. As mentioned, D-dimer level was elevated at admission but had normalized at discharge, and at 4 months follow up. Although elevated D-dimer can indicate a hypercoagulable state, it is a non-specific marker that may also be elevated in various other conditions, including STEMI. After the recurrence of LV thrombus despite adequate triple antithrombotic therapy, laboratory tests for hypercoagulability were performed and all were normal. In our case we did not use GPIIb-IIIa antagonists, but the additive effects of GPIIb-IIIa antagonists and prasugrel’s active metabolite on platelet activation, aggregation, and procoagulant activities have been reported in STEMI patients . Some authors have described prothrombotic genetic polymorphisms, such as PIA2, which is a determinant of ischemic stroke in a selected high-risk hypertensive population , or the single-nucleotide polymorphism of human CaMKIV gene (CaMK4), which plays a pivotal role in blood pressure regulation through the control of endothelial nitric oxide synthase (eNOS) activity. Impairment of CaMK-mediated activation of eNOS, as in CaMK4 gene deletion, induces hypertension, . We were unable to test for genetic polymorphisms related to thrombosis, as described by other authors [12, 13], as such testing is not available in our setting, and this is one of the principal limitations in the management of our patient.
When stent placement is required in a patient who needs subsequent long-term OAC, a bare-metal stent is generally preferred over a DES . In patients without diabetes, small vessels, or large lesions requiring OAC because of atrial fibrillation or LV thrombus, the benefit of using a DES to prevent restenosis may be outweighed by the increased risk of bleeding with long-term triple antithrombotic therapy . A bare-metal stent was not used in our case because the LV thrombus was detected after PCI.
The ACC/AHA guidelines  recommend 12 months of DAPT, but some preliminary data indicate that the rate of stent thrombosis may be very low when DAPT is discontinued at 6 months or maybe even 3 months after placement of a second-generation DES, such as an everolimus- or zotarolimus-eluting stent [15, 16]. The randomized Efficacy of Xience/Promus versus Cypher to Reduce Late Loss in Stent (EXCELLENT) trial compared 6 months versus 12 months of DAPT, and everolimus-eluting versus sirolimus-eluting stents. The trial found that first-generation stents appear to have a higher rate of late stent thrombosis than second-generation stents, and second-generation stents are therefore preferred in patients who need a DES and subsequent triple antithrombotic therapy .
The recent randomized controlled What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing (WOEST) trial  found that among patients who underwent PCI with subsequent OAC, treatment with clopidogrel and OAC was associated with a significantly lower risk of bleeding than treatment with aspirin, clopidogrel, and OAC. The sample size was small, but the investigators saw no evidence of increased risk of thrombotic events by withholding aspirin. This suggests a possible alternative therapeutic approach for patients such as ours, using only OAC and clopidogrel. Physicians should be aware that genetic susceptibility to hypercoagulable states may favor the appearance or persistence of thrombus, related to mechanisms independent of the traditional cardiovascular risk factors. The need to investigate genetic polymorphisms related to thrombosis should be assessed on an individual basis.
The present case illustrates the need for repeat TTE at least 3 months after the withdrawal of OAC in STEMI patients, as recommended by the guidelines. It is important to confirm the resolution of any LV thrombus and associated wall motion abnormalities. When there is occlusion of two or more coronary arteries supplying the apical area, it is not easy to determine which occlusion is related to thrombus formation. In patients undergoing primary PCI who require subsequent OAC, avoidance of a DES is strongly preferred. However, the benefits of a DES over a bare-metal stent may outweigh the risks in some cases. When a DES is deemed necessary, a second-generation stent is preferred if the patient requires subsequent triple antithrombotic therapy. An alternative regimen of OAC and clopidogrel, without aspirin, may be considered in such cases. In patients with recurrent intraventricular thrombus unexplained by inadequate antithrombotic therapy, genetic polymorphisms related to thrombosis should be investigated.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
All authors are staff members of the Department of Cardiology, University Hospital of the Canary Islands, La Laguna, Tenerife, 38320, Spain.
- Stettler C, Allemann S, Wandel S, Kastrati A, Morice MC, Schomig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabate M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, De Carlo M, Erglis A, Chechi T, Ortolani P, Schalij MJ, Diem P, Meier B, Windecker S, Juni P, et al: Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ. 2008, 337: a1331-10.1136/bmj.a1331.PubMedPubMed CentralView ArticleGoogle Scholar
- Steg G, James SK, Atar D, Badano L, Blömstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey K, Valgimigli M, van’t Hof A, Widimsky P, Zahger D: ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012, 33: 2569-2619.PubMedView ArticleGoogle Scholar
- O’Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Kushner FG, Ohman EM, Stevenson WG, Yancy CW: 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. J Am Coll Cardiol. 2013, 61 (4): e78-140. 10.1016/j.jacc.2012.11.019.PubMedView ArticleGoogle Scholar
- You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, Hylek EM, Schulman S, Go AS, Hughes M, Spencer FA, Manning WJ, Halperin JL, Lip GY: Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012, 141: e531S-e575S. 10.1378/chest.11-2304.PubMedPubMed CentralView ArticleGoogle Scholar
- Vandvik PO, Lincoff AM, Gore JM, Gutterman DD, Sonnenberg FA, Alonso-Coello P, Akl EA, Lansberg MG, Guyatt GH, Spencer FA: Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012, 141: 1129-Chest 2012; 141: e637 S–68 S. Erratum in: ChestView ArticleGoogle Scholar
- Douglas PS, Garcia MJ, Haines DE, Lai WW, Manning WJ, Patel AR, Picard MH, Polk DM, Ragosta M, Ward RP, Weiner RB: ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR2011. American college of cardiology foundation appropriate Use criteria for echocardiography task force. J Am Coll Cardiol. 2011, 57 (9): 1126-66. 10.1016/j.jacc.2010.11.002.PubMedView ArticleGoogle Scholar
- Kolh P, Wijns W, Di Danchin N, Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart D: Guidelines on myocardial revascularization. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg. 2010, 38 (Suppl): S1-S52.PubMedView ArticleGoogle Scholar
- Shireman TI, Mahnken JD, Howard PA, Kresowik TF, Hou Q, Ellerbeck EF: Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest. 2006, 130 (5): 1390-1396. 10.1378/chest.130.5.1390.PubMedView ArticleGoogle Scholar
- Huret JF, Gebuhrer V, Shibli H, Fichter P, Grand A: Cerebral embolism disclosing a left intraventricular thrombus 6 years after atypical infarction. Ann Cardiol Angeiol (Paris). 1992, 41 (3): 137-40.Google Scholar
- Kwiecień-Sobstel A, Zabojszcz M, Owsiak M, Bartuś S, Dudek D, Kawecka-Jaszcz K, Mirek-Bryniarska E, Bryniarski L: Patient with left ventricular aneurysm and thrombus after myocardial infarction— long-term observation. Kardiol Pol. 2011, 69 (4): 373-6.PubMedGoogle Scholar
- Berny-Lang MA, Jakubowski JA, Sugidachi A, Barnard MR, Michelson AD, Frelinger AL: P2Y12 Receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity. J Am Heart Assoc. 2013, 2 (3): e000026-10.1161/JAHA.113.000026.PubMedPubMed CentralView ArticleGoogle Scholar
- Lanni F, Santulli G, Izzo R, Rubattu S, Zanda B, Volpe M, Iaccarino G, Trimarco B: The Pl (A1/A2) polymorphism of glycoprotein IIIa and cerebrovascular events in hypertension: increased risk of ischemic stroke in high-risk patients. J Hypertens. 2007, 25 (3): 551-6. 10.1097/HJH.0b013e328013cd67.PubMedView ArticleGoogle Scholar
- Santulli G, Cipolletta E, Sorriento D, Del Giudice C, Anastasio A, Monaco S, Maione AS, Condorelli G, Puca A, Trimarco B, Illario M, Iaccarino G: CaMK4 Gene deletion induces hypertension. J Am Heart Assoc. 2012, 1 (4): e001081-10.1161/JAHA.112.001081.PubMedPubMed CentralView ArticleGoogle Scholar
- Faxon DP, Eikelboom JW, Berger PB, Holmes DR, Bhatt DL, Moliterno DJ, Becker RC, Angiolillo DJ: Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost. 2011, 106 (4): 572-84. 10.1160/TH11-04-0262.PubMedView ArticleGoogle Scholar
- Leon MB, Kandzari DE, Eisenstein EL, Anstrom KJ, Mauri L, Cutlip DE, Nikolsky E, O’Shaughnessy C, Overlie PA, Kirtane AJ, McLaurin BT, Solomon SL, Douglas JS, Popma JJ, ENDEAVOR IV Investigators: Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (randomized, controlled trial of the Medtronic endeavor drug [ABT-578] eluting coronary stent system versus the taxus paclitaxel-eluting coronary stent system in De novo native coronary artery lesions). JACC Cardiovasc Interv. 2009, 2: 1208-1218. 10.1016/j.jcin.2009.10.008.PubMedView ArticleGoogle Scholar
- Caixeta A, Lansky AJ, Serruys PW, Hermiller JB, Ruygrok P, Onuma Y, Gordon P, Yaqub M, Miquel-Hebert K, Veldhof S, Sood P, Su X, Jonnavithula L, Sudhir K, Stone GW, SPIRIT II and III Investigators: Clinical follow-up 3 years after everolimus-and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions) and SPIRIT III (A clinical evaluation of the investigational device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the treatment of subjects with de novo native coronary artery lesions) randomized trials. JACC Cardiovasc Interv. 2010, 3: 1220-1228. 10.1016/j.jcin.2010.07.017.PubMedView ArticleGoogle Scholar
- Park KW, Yoon JH, Kim JS, Hahn JY, Cho YS, Chae IH, Gwon HC, Ahn T, Oh BH, Park JE, Shim WH, Shin EK, Jang YS, Kim HS: Efficacy of Xience/promus versus Cypher in rEducing Late Loss after stENTing (EXCELLENT) trial: study design and rationale of a Korean multicenter prospective randomized trial. Am Heart J. 2009, 157: 811-817 e1. 10.1016/j.ahj.2009.02.008.PubMedView ArticleGoogle Scholar
- Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, Adriaenssens T, Vrolix M, Heestermans AA, Vis MM, Tijsen JG, van ’t Hof AW, ten Berg JM, WOEST study investigators: Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013, 381 (9872): 1107-15. 10.1016/S0140-6736(12)62177-1.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.